Luigi Dogliotti

TL;DR: GC provides a similar survival advantage to MVAC with a better safety profile and tolerability, and this better-risk benefit ratio should change the standard of care for patients with locally advanced and metastatic TCC from MVAC to GC.

TL;DR: Compared with a large randomized phase III study of GC versus MVAC, long-term survival in patients with locally advanced or metastatic transitional cell carcinoma of the urothelium treated with gemcitabine/cisplatin or methotrexate/vinblastine/doxorubicin/c isplatin was similar in both arms.

TL;DR: Adjuvant mitotane treatment had a significant advantage for recurrence-free survival in patients with radically resected adrenocortical carcinoma, and temporary dose reduction was needed in 13% of patients.

TL;DR: It is confirmed that subjects undergoing computerized tomography scan of the chest in a screening program of lung cancer in Piedmont are presently able to identify incidentally discovered adrenal masses more often than in early years and that the prevalence of adrenal incidentalomas on CT images is approaching that of autopsy series.

TL;DR: 1 year of extended adjuvant therapy with neratinib, administered after chemotherapy and trastuzumab, significantly reduced the proportion of clinically relevant breast cancer relapses-ie, those that might lead to death, such as distant and locoregional relapses outside the preserved breast-without increasing the risk of long-term toxicity.